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Libby, Andrew Eric (M.S., Chemistry) 
 
NMR Resonance Assignment of the Therapeutic RNA Aptamer Macugen in 
Complex with its in Vivo Target, the Heparin Binding Domain of VEGF165  
Thesis directed by Professor Arthur Pardi 
 
 Aptamers consist of nucleic acids that are selected from an in vitro library in 
order to bind a specific target or catalyze a reaction.  Many aptamer-ligand structures 
have been solved in recent years to characterize the molecular mechanisms that 
explain the high affinity and specificity observed in these interactions.  To this end, 
NMR resonance assignment experiments were performed as a necessary first step to 
calculating the solution structure of a therapeutically-active RNA aptamer, Macugen, 
bound to its in vivo target, the heparin binding domain (HBD) of vascular endothelial 
growth factor 165 (VEGF165).  Though the resonance assignment of Macugen is 
challenging due to its inability to be isotopically-labeled, techniques were employed 
that take advantage of the unique chemical modifications of this nucleic acid that are 
not present in traditional, unmodified RNA.  Using the information obtained from 
two-dimensional heteronuclear (
19
F, 
1
H) and homonuclear (
1
H, 
1
H) experiments, 
assignments were made for a sizable number of Macugen atoms.  The assignments 
made in this work will be necessary to calculate a solution structure to better 
understand the molecular mechanisms that give rise to the high affinity and 
specificity observed in the Macugen-HBD complex. 
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CHAPTER 1 
Background and Introduction 
 
1.1 Introduction to aptamers and the SELEX process  
Aptamers consist of RNA or DNA molecules that are produced in vitro with 
the purpose of binding a specific target or catalyzing a certain reaction [1-3].  For 
instance, there currently exist aptamers that bind a variety of biomolecules such as 
proteins, viruses, nucleic acids, aminoglycosides, vitamins, cofactors, and even whole 
tissues via cell-surface protein recognition [1, 4-6].  Additionally, aptamers have also 
been developed to bind an assortment of synthetic molecules, including drugs and 
organic dyes [7-9].  Like antibodies, aptamers have been shown to bind targets with 
remarkable affinity and specificity [7, 9, 10].  Importantly, many aptamers have also 
been produced to catalyze specific chemical reactions, such as the hydrolysis and 
isomerization of small molecules [3, 11]. Thus, aptamers have potential for use in a 
wide array of applications, including biosensing, therapeutics, bioanalytical 
chemistry, and tools for the biotechnology industry [12-15].   
The process by which aptamers are produced in vitro is known as Systematic 
Evolution of Ligands by EXponential Enrichment, or SELEX.  Functional RNA or 
DNA molecules are obtained by first constructing large libraries of unique nucleic 
acids (up to 10
14
) containing regions of random sequence, and by then applying 
selective pressures to isolate species within the library that are capable of binding a 
ligand [1, 2].  For example, a large pool of randomized nucleic acids may be 
incubated with a target protein ligand and then subjected to partitioning procedures 
2 
 
that sequester sequences that exhibit binding affinity to the protein [9].  The isolated 
species are subsequently amplified and subjected to further rounds of selection, 
resulting in an enriched fraction of nucleic acids from the original pool that are able 
to bind a specific target with considerable affinity.  If desired, the SELEX experiment 
can be designed to produce species capable of catalyzing specific reactions (rather 
than solely binding a target) [16].  
The basis for the discrimination and affinity that aptamers display for ligands 
has been a topic of great interest [17-19].  For example, considerable work has been 
done to understand the binding mechanisms involved in complex formation.  It has 
been shown that many aptamers do not adopt rigid conformations prior to ligand 
binding [20].  Rather, these complexes appear to form via induced-fit mechanisms, or 
so-called conformational capture [19-22].  Importantly, this adaptive recognition 
process closely parallels the mechanism by which many natural RNA molecules (and 
enzymes) bind in vivo targets with high affinity and specificity, although it has been 
proposed that aptamers selected purely for high affinity don‘t necessarily carry the 
ability to completely discriminate between very closely-related targets [17, 18, 20, 
21].  Utilizing high affinity and specificity as selective pressures in SELEX 
experiments may be necessary to achieve high affinity/specificity for some aptamer-
ligand systems [18].   
Also of interest are the types of molecular interactions that give rise to the 
high affinity and specificity observed in aptamer-ligand complexes.  Accordingly, a 
variety of aptamer-ligand structures have been solved in order to elucidate these 
interactions [4, 6, 22-26].  Features common to aptamer-ligand complexes include 
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shape/charge complementarity between aptamer/ligand binding surfaces, specific 
hydrogen bonding networks, and unique aromatic stacking [8, 19].  It has also been 
found that aptamers tend to fold around and enclose large areas of the ligand, thereby 
allowing a significant number of specific intramolecular contacts to be made [19].  
Interestingly, several novel RNA//DNA folds have been discovered by studying 
aptamer-ligand complexes [24, 27].  The emergence of additional aptamer-ligand 
structures continues to promote understanding of the molecular mechanisms by which 
these nucleic acids bind to such diverse ligands with high specificity and affinity.  
Indeed, it is a long-term goal of this project to understand the molecular basis for one 
such complex by examining its structure. 
 
1.2 Vascular Endothelial Growth Factor (VEGF) as a SELEX target 
Vascular endothelial growth factor (VEGF) is a hypoxia-inducible angiogenic 
growth factor which plays a vital role in many physiological processes [28].   Cells 
deficient in oxygen express hypoxia-inducible factor (HIF), a transcription factor, 
which stimulates the production and extracellular release of VEGF [29].  VEGF, a 45 
kDa homodimer, binds to its receptors on the surface of vascular endothelial cells, 
leading to phosphorylation of the receptors and a subsequent signaling pathway that 
promotes nascent blood vessel growth [28, 30].  VEGF is a vital component of many 
physiologically-important processes, including regular maintenance of the 
vasculature, embryogenesis, and wound healing [31, 32].  However, in addition to its 
normal functions, VEGF has also been widely implicated in a number of pathological 
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processes including inflammation, rheumatoid arthritis, cancer, and the wet form of 
age-related macular degeneration (AMD) [33, 34]. 
In humans, four predominant VEGF splice-variants have been identified and 
are designated according to their number of amino acids: VEGF121, VEGF165, 
VEGF189, and VEGF206 [28].  All variants contain an identical N-terminal receptor 
binding domain (RBD), though they are otherwise unique in their structural make-up 
and functionality [28, 31].  VEGF189 and VEGF206 are almost exclusively segregated 
to the extracellular matrix, whereas VEGF121 and VEGF165 are soluble and can 
diffuse once exported.  In addition, VEGF165 contains a unique 55-amino acid 
heparin-binding domain (HBD) found at the C-terminus that is not present in the 
other soluble variant, VEGF121 [35, 36].  Notably, VEGF165 has been identified as the 
primary isoform implicated in disease [28].  
Due to its prominent role in pathological conditions, VEGF has been 
identified as a significant therapeutic target [37, 38].   One historical challenge to 
designing VEGF inhibitors is that it is difficult to specifically target the disease-
implicated isoform (VEGF165)  [39].  As stated previously, all VEGF variants contain 
a receptor binding domain (RBD), and one of the first inhibitors developed against 
VEGF was the soluble form of the VEGF receptor [40].  While limiting or possibly 
halting the progression of disease, it is unknown whether species that therapeutically 
target VEGF via the RBD may also negatively affect blood vessel formation during 
normal, healthy processes since all isoforms contain this moiety [39].  Several 
successful and clinically-effective agents have been produced that target all VEGF 
variants indiscriminately, although development of inhibitors that bind only VEGF165 
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remains desirable [39, 41].  Importantly, because SELEX can produce species capable 
of binding a ligand with high affinity and specificity, this method was viewed as a 
fitting candidate for developing therapeutic agents that can effectively bind and 
discriminate between various isoforms of a protein such as VEGF.   
  To this end, the SELEX process was employed by Jellinek and coworkers in 
the mid-nineties to develop nucleic acid aptamers that bind the 165-amino acid VEGF 
isoform [42].  The aptamers that were obtained from this original SELEX experiment 
were enriched from a library of 10
14
 unique RNA molecules, each containing a region 
of 30 randomized nucleotides (the evolved region).  Aptamers were obtained that 
bound VEGF165 with high affinities ranging from 0.2 nM to 20 nM, and can be 
categorized into six main families based on consensus in sequence in the randomized 
region.  The aptamers from this experiment are shown in Figure 1.1. 
Importantly, it was found that heparin effectively competes with these 
aptamers for VEGF165 binding, suggesting that these nucleic acids may interact with 
the heparin binding domain (HBD) of the protein (a unique component found in 
VEGF165 that is not present in the other soluble isoform, VEGF121) [28, 42]. 
Therefore, it is likely that these aptamers possess the ability to discriminate between 
the soluble isoforms of VEGF—a beneficial property that other inhibitors to the 
growth factor did not previously exhibit at the time [39, 41].  In addition, the enriched 
nucleic acids were shown to effectively inhibit binding of VEGF165 to its receptors on 
human umbilical vein endothelial cells in a concentration-dependent manner [42].  
Hence, this work provided robust evidence that the SELEX process could potentially  
be employed to produce therapeutically-active species that target the disease- 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Unmodified RNA aptamers selected against VEGF165.  Jellinek et al. 
selected aptamers from a library of 10
14 
unique RNA molecules, each with a region of 
30 random nucleotides.  Aptamers found to effectively bind VEGF165 can be divided 
into six main families based on sequence consensus.   
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implicated form of VEGF with high affinity and specificity.  Aptamers were 
truncated to their minimally-functional sequences and, to further enhance resistance 
to degradation, most purine residues were changed to 2‘-OMe-containing analogs.  
After testing for retention of binding activity, the resulting product was a series of 
degradation-resistant, chemically-modified RNA aptamers that bind VEGF165 with 
extremely low dissociation constants ranging from 49 pM to 130 nM [42].   
 
1.3 Development of chemically-modified RNA aptamers to bind VEGF165    
Chemical and physical stability are important determinants of pharmaceutical 
efficacy [43].  For example, RNA aptamers used in therapeutic applications must be 
resistant to base-catalyzed hydrolysis.  Various strategies are currently used to 
stabilize aptamers, including substitution of the 2‘-OH on ribose sugars with 2‘-fluoro 
(2‘-F) or 2‘-O-methyl (2‘-OMe) groups in order to prevent the 2‘ oxygen from 
attacking the phosphate backbone [13].  Due to the possible therapeutic potential of 
previous aptamers developed to target VEGF165, Ruckman and coworkers carried out 
three separate SELEX experiments with 2‘-F pyrimidine nucleotides to obtain a set of 
degradation-resistant aptamers that bind VEGF165 with high affinity [44].   
The chemically-modified (2‘-F pyrimidine and 2‘-OMe purine) RNA 
aptamers produced from this work can be grouped into three distinct families based 
on consensus sequence in the random sequence region (30 and 40 nucleotides).  
These aptamers do not show binding affinity for VEGF121, indicating they are able to 
effectively discriminate between the two soluble forms of VEGF.  Additionally, 
similar to the original unmodified RNA aptamers, it is likely that the HBD of 
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VEGF165 is heavily involved in the aptamer-protein binding interaction; experiments 
showed photo-crosslinking between uracil residues of the aptamers and Cys
137
 located 
in the HBD of the protein [42].  Finally, it was shown that these aptamers were able 
to inhibit binding of VEGF165 to its receptor on porcine aortic endothelial cells, 
thereby demonstrating their possible use as potent inhibitors [42].  Due to their 
resistance to degradation, their ability to bind to the disease-implicated isoform of 
VEGF with high affinity/specificity, and their ability to inhibit binding of VEGF165 to 
its receptors, these aptamers were considered to have high therapeutic potential. 
. 
1.4 Characteristics of the Macugen-VEGF165 complex and the role of the HBD in 
binding        
One of the chemically-modified RNA aptamers that targets VEGF165 was 
approved by the FDA in 2004 to treat the wet form of age-related macular 
degeneration (AMD), thus becoming the first therapeutic aptamer on the market [37].  
Known as Macugen (pegaptanib sodium), this 28-nucleotide aptamer is delivered via 
intraocular injection and binds VEGF165 with very high affinity (Kd = 50 pM) to limit 
progression of the eye disease.  Additionally, Macugen significantly decreases 
vascular permeability (the ability of small molecules and ions to penetrate the 
vascular wall)—a pathological characteristic of wet AMD [44, 45].  The aptamer is 
highly resistant to degradation; chemical modifications include 2‘-F pyrimidines, 2‘-
OMe groups on all but two purines, and an added thymidine to the 3‘ terminus via a 
reversed 3‘-3‘ linkage.  The sequence and secondary structure of Macugen are shown 
in Figure 1.2. 
9 
 
Work has been done to show that Macugen specifically targets the 55-amino 
acid HBD of VEGF165—an N-terminal domain that is not present in VEGF121, the 
other soluble form of the growth factor [45].  The ability of Macugen to bind the HBD 
likely gives rise to its ability to discriminate between the two soluble isoforms to 
directly target the disease-implicated variant.  As mentioned previously, Macugen 
demonstrated photo-crosslinking between 5–iodo-modified U14 in the hairpin loop 
and Cys
137
 of the HBD [44].  Additionally, in vivo experiments have shown that free 
HBD can efficiently compete with the full-length protein for aptamer binding, thus 
providing further evidence that this domain is targeted by Macugen [45].  
Furthermore, studies have determined that the majority of the binding energy comes 
from interactions between Macugen and the HBD; the aptamer binds free HBD with a 
dissociation constant of 12 nM (∆Gº = -10.8 kcal/mol), compared to a Kd of 50 pM 
(∆Gº = -14.0 kcal/mol) for the full-length protein [45].  
Nuclear magnetic resonance (NMR) methods have also been employed to 
confirm that the HBD is primarily targeted in the Macugen-VEGF165 interaction.  
Chemical shifts of protein backbone amides can be monitored via 
15
N
 
-
1
H 
 
correlation 
experiments (
15
N, 
1
H 
 
HSQC) to observe different folding patterns or changes in the 
local chemical environment—common occurrences in complex formation [46, 47].  
15
N, 
1
H HSQC experiments have shown that the chemical shifts of many backbone 
amide residues in the HBD are significantly perturbed upon binding to Macugen, 
indicating that there are direct interactions between the HBD and aptamer [45].   
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Figure 1.2   The sequence, secondary structure, and chemical modifications of 
Macugen.  This 28-nt, chemically-modified RNA was obtained through SELEX and 
was found to effectively inhibit angiogenesis by targeting the heparin binding domain 
(HBD) of VEGF165.  Except for A4 and A5, all purines contain 2‘-O-methyl (2‘-
OMe) modifications for increased stability and nuclease resistance.  All pyrimidines 
contain a 2‘-fluoro (2‘-F) moiety.  U14 was found to form a crosslink with Cys137 of 
VEGF165.   The 3‘ terminus of the aptamer contains a deoxythymidine (dT28) 
reverse-linked (3‘—3‘) to G27 to protect against exonuclease activity. 
BULGE 
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Equally important, the unique 
15
N, 
1
H HSQC fingerprint of free HBD bound to 
Macugen is also seen in the 
15
N, 
1
H HSQC spectrum of the full-length protein bound 
to the aptamer, demonstrating that the HBD adopts the same conformation in both the 
Macugen-HBD and Macugen-VEGF165 complexes [45].    
NMR studies have also shown that Macugen adopts the same conformation 
when bound to either full-length VEGF165 or the HBD alone [45].  1D imino proton 
spectra of the HBD- and full-length-bound complexes are extremely similar, 
suggesting that the nucleic acid‘s secondary structure is equivalent in the complexes 
[45].  Additionally, 
31
P NMR can be used as a sensitive probe for detecting even 
slight conformational differences in ribose-phosphate backbones of nucleic acids 
[48].  1D 
31
P NMR spectra of Macugen complexed with both the HBD and  the full-
length VEGF165 are essentially identical, providing further evidence that Macugen 
conformation is the same in these complexes [45].  Notably, Ca
2+
 is a required 
component for Macugen-VEGF165 binding, and this dependence has also been 
observed for Macugen-HBD complex formation [44, 45].  However, the presence of 
Ca
2+
 does not affect NMR spectra of either free species (Macugen or HBD), 
suggesting that this divalent cation is mediating an interaction between the aptamer 
and HBD [45].  The above work provides solid evidence that the HBD is specifically 
targeted by Macugen, and that this domain can be used for further studies in order to 
understand the binding mechanisms/interactions of the aptamer with its protein 
ligand. 
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1.5 The need for Macugen NMR resonance assignments 
 The remarkably high affinity and specificity exhibited by Macugen for 
VEGF165 has generated interest in understanding the fundamental mechanisms that 
govern this interaction.  To examine the types of molecular interactions occurring in 
the Macugen-HBD complex, NMR is being used to obtain a solution structure.  
Solution structures are solved using dihedral angle constraints and inter-atomic 
distances derived from nuclear Overhauser effects (NOEs) to calculate conformations 
with low free energies [47].  To do this, it is necessary to first assign resonances in 
NMR spectra to their associated nuclei. A historic difficulty with assigning 
resonances of large biomolecules or complexes is that, due to the large number of 
atoms and associated NMR signals, it is often challenging to make unambiguous 
assignments [49].  Spectral overlap and crowding of peaks in conventional 
homonuclear 1D and 2D experiments become highly problematic as the size of the 
biomolecule increases.  Modern methods have addressed this by making use of 
isotopically-labeled (
15
N, 
13
C, 
2
H) biomolecules and unique multidimensional 
heteronuclear NMR experiments [47].  One advantage of isotopic labeling is that 
peaks can be separated in multiple dimensions, thereby reducing spectral 
overlap/crowding and increasing the odds of unambiguous resonance assignment.     
Expression of isotopically-labeled proteins has become a common practice, 
and the use of this strategy in conjunction with multi-dimensional heteronuclear 
NMR has been employed in our lab to confidently assign the resonances of most 
atoms of the HBD in complex with Macugen [unpublished data].  The process is 
fairly straight-forward; multidimensional heteronuclear NMR experiments are first 
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conducted that correlate resonances belonging to atoms of individual spin systems 
(amino acids), and then the spin systems are assembled sequentially using knowledge 
of the protein‘s sequence and experiments that correlate resonances across the amide 
bond [47].  Thus, once the spin systems are connected sequentially, chemical shifts of 
atoms belonging to each amino acid can be confidently assigned.  A similar process is 
typically used to accurately assign chemical shifts in isotopically-labeled nucleic 
acids.  Experiments are done that reveal resonances in individual spin systems (sugars 
and bases), and then the spin systems are connected sequentially (sugar-to-base 
walking) using prior knowledge of the nucleic acid sequence and experimentally-
obtained NOEs between atoms on neighboring residues.        
Unfortunately, Macugen cannot be isotopically labeled, thereby making 
resonance assignment of its atoms a challenging task due to reasons described earlier.  
First, in vitro transcription of Macugen using 2‘-F pyrimidines is not efficient enough 
to yield quantities of the aptamer needed for multi-dimensional NMR experiments.  
Also, it has been shown that binding is not retained when Macugen is transcribed 
using 2‘-OH pyrimidines [unpublished data].  For these reasons, Macugen needs to be 
chemically-synthesized in order to produce the required quantities for NMR.   At 
present, isotopically-labeled 2‘-F phosphoramidites are not available for use in 
synthesis, so isotopically-labeled Macugen cannot be obtained for use in NMR 
resonance assignment experiments.  In order to assign resonances of Macugen atoms, 
more traditional NMR experiments must be employed, and nonstandard strategies 
must be developed to assign chemical shifts with a high degree of certainty.   
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1.6 Project description and overview of thesis 
 The long-term goal of this project is to understand the types of molecular 
interactions that allow Macugen to specifically target the HBD of VEGF165 with 
extremely high affinity and specificity.  To this end, work is being done to obtain a 
solution structure of the Macugen-HBD complex.  This thesis specifically addresses 
the need for NMR resonance assignments of the bound aptamer with the goal of 
obtaining a structure in the future.  Assignments used in structure calculation must be 
accurate, so a novel approach was devised that used the 2‘-F and 2‘-OMe chemical 
modifications to strategically identify resonances.  The modifications allow for more 
confident assignment of Macugen compared to unmodified RNA of similar size.        
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CHAPTER 2 
Methods 
 
2.1 Preparation of HBD of VEGF165 for NMR studies 
 The 
15
N-labeled HBD of VEGF165 was expressed and purified for NMR 
experiments in complex with Macugen as described previously [45].  Protein was 
expressed in P. Pastoris for a period of 48 hours (slightly differing from the original 
protocol which calls for an expression time of 36 hours).  Though the 
15
N- labeling of 
this protein is not necessary for sequential assignment of Macugen, it does allow for 
future multidimensional NMR experiments that probe the behavior of the HBD in the 
complex.  The HBD was purified on a heparin Sepharose column and exchanged into 
the following buffer (NMR buffer): 100% D2O, 100 mM NaCl, 10 mM Tris-d11 
(pH=7.0), 1 mM CaCl2, 0.01 mM EDTA, and 0.05% NaN3.  The protein was 
concentrated using Centricon YM-3 centrifugal filter devices to a volume of 310 µL, 
and the concentration was found to be 1 mM from a BCA assay.   
 
2.2 Preparation of the Macugen-HBD complex for NMR studies 
 Non-pegylated Macugen was obtained from NeXstar pharmaceuticals.  The 
amount of aptamer necessary for producing a 0.95 mM NMR sample (at a volume of 
310 µL) was aliquoted and buffer-exchanged into D2O (pH=7.0).  After buffer 
exchange, the aptamer was lyophilized and subsequently dissolved into the HBD 
sample to form the complex.  It is important to note that NMR studies conducted to 
sequentially assign Macugen should optimally be performed in a slight excess of 
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HBD (as opposed to a 1:1 ratio).  This excess helps to ensure that all Macugen is in 
complex with HBD, and that signals obtained in NMR studies can confidently be 
attributed to the bound form.  The concentration of HBD in the experiments was 1 
mM, thus Macugen was chosen to be at a concentration of 0.95 mM.  To ensure that 
all aptamer was bound, a 2D 
1
H, 
1
H TOCSY spectrum of this complex was obtained 
and then compared to spectra previously acquired for free Macugen.  No H5/H6 
peaks arising from the free aptamer were seen in the prepared complex meaning all 
aptamer was bound.  Additionally, the TOCSY spectrum was compared to that of a 
previously-prepared Macugen-HBD complex, and they were found to be identical.  
Therefore, it was determined that the NMR sample was sufficient for assignment 
studies. 
 
2.3 Acquisition of a 2D 
1
H, 
1
H TOCSY spectrum to identify pyrimidine H5/H6 
resonances in the Macugen-HBD complex  
 A 
1
H, 
1
H TOCSY spectrum was first collected to obtain H5/H6 resonances of 
Macugen 2‘-F pyrimidines [50].  The experiment was performed at 25ºC on a 500 
MHz Varian spectrometer using a 
1
H/
13
C/
15
N triple resonance probe with z-axis 
pulsed field gradients.  The sequence was run with a 48 ms mixing time (achieved by 
using 24 MLEV-17 cycles with a 30 µs spinlock time), and a 32-step z-filter phase 
cycle was applied to remove zero quantum peaks [27].   2048 complex points were 
taken in t2, and 195 complex points in t1.  The sweep-width was set to 5006 Hz in 
both dimensions.  The data was processed using NMRPipe, and cosine bell window 
functions were applied in each dimension.  Cross-peaks corresponding to pyrimidine 
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H5/H6 resonances were located and temporarily given arbitrary designations until 
they were assigned to specific pyrimidines. 
 
2.4 Acquisition of a 2D 
19
F, 
1
H HMQC to identify pyrimidine H1’, H2’, H3’ and 
2’-F resonances in the Macugen-HBD complex 
 A unique property of Macugen that makes assignment easer compared to 
unlabeled RNA of similar size is its chemical modifications.  Fluorine is an NMR-
active nucleus, so experiments can be employed that use this nucleus to aid in 
resonance assignment.  One way in which this group can be exploited is to perform 
through-bond heteronuclear correlation experiments to obtain assignments for 
individual spin systems (i.e. sugars) [51].  A 2D 
19
F, 
1
H HMQC was acquired to 
identify chemical shifts of pyrimidine sugar protons (H1‘, H2‘, and H3‘) correlated to 
the 2‘ fluorine resonance.  The experiment was conducted at 25ºC on a 500 MHz 
Varian spectrometer using a 
19
F/
1
H probe, and 
19
F decoupling was not used during 
acquisition (t2).  For this experiment, 2048 complex points were collected in t2, and 
106 complex points were acquired in t1.  A sweep width of 5006 Hz was used for both 
dimensions.  The spectrum was processed using NMRPipe, and a cosine bell window 
function was applied in each dimension.  H1‘, H2‘, and H3‘ chemical shifts were 
identified based on their location in the spectra and their observed couplings.  
Resonances were given temporary designations until permanently assigned.    
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2.5 Acquisition of a 2D 
19
F, 
1
H HOESY on the Macugen-HBD complex to 
identify H1’, H2’, H3’ resonances and obtain sequence-specific information  
2D 
19
F, 
1
H heteronuclear Overhauser effect spectroscopy (HOESY) was 
employed to compliment/confirm the information obtained from the 
19
F, 
1
H HMQC, 
and it was also used to identify the chemical shift of the H6 or H8 of nucleotides 
directly following pyrimidines in the 5‘ to 3‘ direction in the sequence [52].  A 2D 
19
F, 
1
H HOESY was performed at 25ºC on a 500 MHz Varian spectrometer using a 
19
F/
1
H probe and a mixing time of 300 ms.  No 
19
F decoupling was applied during t2 
(acquisition).  The experiment was collected with 352 scans per increment, 160 
complex data points in t1, and 4096 complex points in t2.  A sweep width of 7400 Hz 
was chosen for t1, while the sweep width for t2 was set to 6000 Hz.  Using NMRPipe 
for processing, baseline correction was achieved by polynomial time-domain solvent 
subtraction.  Furthermore, an exponential window function with a line broadening of 
5 Hz was applied in the proton dimension while a cosine squared window function 
was used for the fluorine dimension.  The spectrum was compared to the 
19
F, 
1
H 
HMQC in order to validate the information obtained from that experiment, and it was 
also used to locate chemical shifts of H6/H8 protons belonging to residues following 
pyrimidines in the sequence. 
 
2.6 Collection of a 2D 
1
H, 
1
H NOESY in D2O on the Macugen-HBD Complex to 
make sequential assignments 
A 2D 
1
H, 
1
H NOESY was acquired at 25ºC in 100% D2O.  The spectrum was 
acquired on an 800 MHz instrument equipped with a 
1
H/
13
C/
15
N triple resonance cold 
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probe with z-axis pulsed field gradients [53].  A 200 ms mixing time was utilized, and 
water suppression was achieved through presaturation.  NOESY data was collected 
with 80 scans per increment, 400 complex points in the t1 dimension, and 4096 
complex points in the t2 dimension.  The spectral width was set to 10000 Hz in the t1 
dimension and 12019 Hz in the t2 dimension.  The data was processed with 
NMRPipe.  Baseline correction was achieved with polynomial time-domain solvent 
subtraction, and a cosine bell window function was applied in each dimension.   
Pyrimidine H6-H5 NOEs were identified by their direct overlap with H6-H5 TOCSY 
cross-peaks.  This spectrum was then used in conjunction with the 2D 
1
H, 
1
H 
TOCSY, the 2D 
19
F, 
1
H HMQC, and the 2D 
19
F, 
1
H HOESY to examine intra- and 
inter-residue NOEs and make sequential assignments.      
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CHAPTER 3 
Results and Discussion 
 
3.1 Comparison of traditional assignment strategy for unlabeled nucleic acids 
with the Macugen assignment process 
The basic strategy for assigning unlabeled RNA consists of two phases.  First, 
through-bond experiments can be used to identify resonances belonging to individual 
spin systems (sugars and bases). Homonuclear correlation experiments such as the 
1
H, 
1
H COSY and 
1
H, 
1
H TOCSY can be used to identify nucleobase resonances (i.e. 
H5/H6) as well as resonances belonging to sugar resonances (H1‘, H2‘, H3‘, etc) 
[49].  However, through-bond experiments do not provide enough information to 
confidently assign resonances to specific residues in large, unlabeled RNAs [54].  For 
example, a resonance may be identified as belonging to an H6 proton, but without the 
availability of additional methods, this atom cannot be assigned to its individual 
nucleotide in the sequence.  Compounding this problem is the fact that it is difficult to 
correlate nucleobase protons with their ribose counterparts using scalar techniques 
(unless the RNA is double-labeled and multi-dimensional NMR techniques are 
utilized).   There has been some success with such experiments as the J-scaled COSY 
for correlating sugar/base protons, but these experiments are restricted to small 
nucleic acids [55].    
To overcome these problems, through-space (dipolar) methods can be 
employed to examine the specific position of spin systems within the sequence [53].  
For example, the 
1
H, 
1
H NOESY can produce inter-spin system NOEs that can be 
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used to conduct a base-to-sugar walk.  This technique involves following NOEs from 
nucleobase protons to the intra-residue sugar H1‘, H2‘, and H3‘ atoms.  From the 
sugar atoms, inter-residue NOEs can be examined to continue the ‗walk‘ to the base 
protons of the following nucleotide in the sequence.  As long as there is a known 
starting point (or if the identity of a residue within the walk can be confirmed), 
sequence-specific assignments can be made with relative ease assuming the walk is 
not interrupted.  Though NOE-based methods overcome the sequence-specific 
assignment problems that scalar techniques possess, they lack the confidence and 
straightforward analysis that are central to through-bond methods.  
1
H, 
1
H NOESY 
spectra of large RNAs often exhibit significant overlap, thereby making it difficult or 
even impossible to perform extensive sugar-to-base walks.  Additionally, NOESY 
spectra are often rather ambiguous; multiple cross-peaks may be seen for the same 
resonance [49].  As a result, confident assignment of all resonances is often 
impractical.   Homonuclear through-bond techniques are often less ambiguous since 
they rely on J-couplings between bonded nuclei and because signals do not overlap to 
the degree observed in NOESY spectra.  Assignment of most large, unlabeled RNAs 
relies on significant contributions from both homonuclear scalar methods and 
through-space experiments.   
 Though homonuclear scalar and dipolar methods can be used in combination 
to compensate for the individual limitations of each other, the information content of 
these experiments is, nevertheless, often inadequate to achieve near-complete 
assignment of large, unlabeled molecules with a high degree of certainty.   This often 
results in attempts to isotopically label the RNA of interest or the use of other 
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techniques to obtain a molecular structure.  The situation can become rather 
complicated if the RNA of interest is limited in quantity or if it cannot be isotopically 
labeled.  One example of such an RNA is Macugen, which can only be obtained in 
small quantities and in unlabeled form.  To assign nucleic acids such as Macugen, 
strategies need to be developed to overcome the limitations of traditional 
homonuclear NMR methods.  Fortunately, Macugen possesses several chemical 
modifications which make it more amenable to assignment compared to unmodified 
counterparts of similar size.  Foremost, 
19
F is a spin-1/2 nucleus and is found at 100% 
natural abundance, thereby making NMR studies of molecules containing this species 
possible [53].  
19
F also displays excellent chemical shift dispersion and is one of the 
most NMR-sensitive nuclei, exhibiting a gyromagnetic ratio very close to that of 
1
H 
(the most sensitive) [53].  Because Macugen contains 2‘-F pyrimidines, unique NMR 
experiments can be performed that are not otherwise utilized with assignment of 
unmodified, unlabeled RNA 
While traditional homonuclear scalar correlation experiments (such as the  
1
H, 
1
H TOCSY) described previously can still be successfully employed to obtain 
valuable information such as H5/H6 resonances, the fluorine modification of 
Macugen makes the use of more powerful heteronuclear experiments possible.  In 
these experiments, the fluorine is essentially acting as an additional dimension by 
which resonances can be separated and identified.  For example, a 2D 
19
F, 
1
H 
heteronuclear multiple quantum coherence (HMQC) spectrum can be used to identify 
chemical shifts of pyrimidine sugar protons (H1‘, H2‘, and H3‘).  Traditional 
strategies used to assign unlabeled RNA may take advantage of a homonuclear 
1
H, 
1
H 
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TOCSY to help identify sugar protons.  While this type of experiment does takes 
advantage of multiple dimensions to ―separate‖ resonances, there are still several 
limitation to using this type of experiment with large molecules.  For instance, all 
protons experiencing 
1
H-
1
H coupling will produce signals, thereby increasing the 
chances that spectral overlap will be problematic.  Through use of the 
19
F, 
1
H HMQC, 
however, only protons that are coupled to fluorine will appear in the spectrum (rather 
than all proton-proton coupled resonances).  Additionally, the 2‘-F modification 
allows pyrimidine sugar resonances to be easily distinguished from those of purines 
in scalar experiments.  Because Macugen does not contain any purine protons 
coupled to fluorine, the signals produced in scalar correlation experiments must 
necessarily come from pyrimidines.  
 The 2‘-F pyrimidine modification carries several other benefits.  First, the 
fluorine imparts a unique germinal coupling to the H2‘ protons that is absent from 
unmodified (2‘-OH) RNA.  H2‘ resonances in spectra that are not decoupled will 
exhibit a splitting due to this germinal coupling, and they will be separated by ~50 
Hz. Geminal coupling is not observed for the H2‘ proton in unmodified RNA because 
the oxygen is not an NMR-active species.  Furthermore, 2‘-OH proton undergoes 
rapid exchange and is not bonded to the oxygen long enough to impart a vicinal 
coupling (via the oxygen) to the H2‘.  Consequently, the H2‘ of unmodified RNA 
experiences only vicinal coupling to the H1‘ and H3‘, and these couplings are rather 
small.   For example, the JH1‘-H2‘ coupling in unmodified RNA ranges from 1 to 8 Hz 
depending on the sugar pucker and associated torsion angle [49].  Thus, the rather 
large and distinctive 
19
F-
1
H coupling allows for easier assignment of H2‘ chemical 
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shifts in Macugen.  The 2‘ fluorine of pyrimidines will also couple to the H1‘ and H3‘ 
protons, inducing a larger splitting in these signals than is normally seen.  In Macugen 
pyrimidines, H3‘ splitting is observed to be about 27 Hz, whereas the H1‘ splitting is 
about 15Hz.   
Unfortunately, the enhanced information obtained from heteronuclear scalar 
experiments utilizing the 2‘-F group is still not sufficient to solve the traditional 
problem of assigning resonances to their sequence-specific nucleotides.  For instance, 
resonances seen in the 
19
F, 
1
H HMQC can be identified as sugar protons, but there is 
insufficient information at this point to be able to assign these resonances to their 
respective residues in the sequence.  Likewise, there is no way to correlate these sugar 
resonances with their intra-residue base protons (H5/H6).  As with traditional 
strategies for assigning unlabeled RNA, through-space (dipolar) techniques must still 
be introduced in order to sequentially assign Macugen.  Fortunately, the chemical 
modifications of Macugen bring unique advantages to the table over traditional 
unmodified RNA.  First, the 2‘-F modification can be used to acquire a 2D 19F, 1H 
heteronuclear Overhauser effect (HOESY) spectrum.  This method identifies 
resonances that exhibit an NOE to the 2‘-F of pyrimidines.  In other words, this 
experiment can provide information about protons that are within ~5.0 Å from the 
fluorine group.  It is important to note that NMR of unmodified RNA does not 
normally make use of the substituent at this position on the ribose; the 2‘-OH proton 
in unmodified RNA undergoes rapid solvent exchange, and it is absent in spectra 
taken in D2O.  The most significant advantage of performing the 
19
F, 
1
H HOESY is 
that it can give vital sequential information about the position of a pyrimidine within 
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the sequence.  This is because the 2‘-F group will exhibit NOEs to the H6/H8 of the 
following residue in the 5‘ to 3‘ direction if the RNA is in A-form conformation (or if 
the fluorine is positioned to do so in other conformations).  Thus, the 
19
F, 
1
H HOESY 
provides inter-residue information about the H6/H8 resonance belonging to the next 
nucleotide in the sequence.  Though similar information can be obtained from the 2D 
1
H, 
1H NOESY (via H2‘/H3‘ NOEs to the following residue), the 19F, 1H HOESY is 
not subject to the severe overlap that the traditional proton-proton NOESY is.  
Finally, the 
19
F, 
1
H HOESY can be used to validate the information obtained from the 
19
F, 
1H HMQC since ribose sugar protons (H1‘, H2‘, and H3‘) are in proximity to the 
fluorine group.   
The 2‘-OMe modification on Macugen purines is also of substantial 
importance, and like the 2‘-F, this group has several benefits that make assignment 
more amenable than unmodified (and unlabeled) RNA.  Information derived from this 
modification is extremely valuable due to the fact that this substituent occupies a 
position on the ribose that is not normally utilized in NMR experiments (the proton of 
2‘-OH is exchangeable).  Next, the 2‘-OMe protons lie between 3 and 4 ppm and will 
thus show signals in a region of the 
1
H, 
1
H NOESY where resonances are not 
normally observed with unmodified RNA.  Like the 2‘-F, the purine 2‘-OMe protons 
can exhibit NOEs to the H6/H8 of neighboring (3‘) residues, thus providing 
information regarding the position in the sequence.  The 2‘-OMe protons can also 
exhibit NOE cross-peaks to the H1‘ and H2‘ sugar protons, thus providing a means to 
substantiate these assignments.  In addition to looking for NOEs between the sugar 
protons and the H8 of purines, NOEs can also be found between said protons and the 
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2‘-OMe group.  Finally, Macugen also contains a deoxythymine (dT28) which is 
reverse-linked (3‘—3‘) at the 3‘ terminus.  Unlike traditional RNA that lacks such a 
residue, distinct signals will be seen which can be attributed to dT28.  For instance, 
the C7 methyl protons of dT28 are found at 1.7 ppm.  Because of the unique 
heteronuclear experiments that can be performed using the 2‘-F, the special properties 
that fluorine imparts (such as the distinct couplings), the advantages of the 2‘-OMe 
groups, and the presence of a terminal deoxy residue, a large deal of Macugen 
residues were able to be confidently assigned.  Importantly, due to these 
modifications, Macugen is more amenable to the assignment process than unlabeled, 
unmodified RNA molecules of similar size.    
 
3.2 Identification of pyrimidine H5/H6 resonances from the 2D 
1
H, 
1
H TOCSY 
 A 2D 
1
H, 
1
H TOCSY was first collected to identify pyrimidine H5/H6 
resonances.  This through-bond experiment correlates multiple proton resonances that 
are coupled within a spin system.  Both C and U exhibit identical spin systems 
consisting of the coupled H5 and H6 protons. Figure 3.1 shows the assigned 
1
H, 
1
H 
TOCSY spectrum collected on the Macugen-HBD complex, and Table 3.1 gives the 
chemical shifts for each assignment.  The cross-peaks for these resonances are well-
dispersed and occur in a distinct region of the spectrum (~5.0-6.5 ppm for H5 and 
~6.5-9.0 ppm for H6), so spectral crowding is not a problem.  It should be noted that 
purine nucleobase resonances cannot be established with this type of experiment 
since there are no coupled protons in these spin systems (the labile imino/amino 
protons are not coupled to the carbon-bound protons).  Though the pyrimidine H5/H6     
27 
 
 
Figure 3.1 2D 
1
H, 
1
H TOCSY spectrum of the Macugen-HBD complex expanded on 
pyrimidine H5/H6 resonances. A 2D 
1
H, 
1
H TOCSY spectrum with a 48 ms mixing 
time was collected at 500 MHz.  All 13 expected H5/H6 peaks are seen on both sides 
of the diagonal. 
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Table 3.1 Final pyrimidine H5/H6 assignments in the 
1
H-
1
H TOCSY spectrum of the 
Macugen-HBD complex.  
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resonances obtained from the 
1
H, 
1
H TOCSY cannot be assigned to their sequence-
specific nucleotide from this spectrum alone, the experiment is necessary for several 
reasons.  First, acquisition of the 
1
H, 
1
H  TOCSY provides resonances to which 
pyrimidine sugar protons can be correlated to during initial base-to-sugar walks in the 
1
H, 
1
H NOESY spectrum.  Additionally, acquisition of the 
1
H, 
1
H TOCSY allows the 
H5/H6 NOESY cross-peaks to be easily located since it can simply be overlaid onto 
the 
1
H, 
1
H NOESY spectrum.     
  
3.3 Identification of pyrimidine H1’, H2’, and H3’resonances from the 2D 19F, 1H 
HMQC 
 Next, a 
19
F, 
1
H HMQC was acquired to obtain resonances for pyrimidine 
sugar protons, including the H1‘, H2‘, and H3‘.  This experiment correlates protons 
and fluorine atoms that are coupled within individual spin systems.  Because only 
pyrimidines contain the 2‘-F group, no purine sugar resonances will be seen in this 
experiment.  Figure 3.2 shows the full 
19
F, 
1
H HMQC spectrum with final 
assignments.  There are several notable features of this spectrum as seen in Figure 
3.3.  First, with the exception of U14, H1‘ protons are located the farthest downfield 
and the H3‘ protons are located the farthest upfield (with the H2‘ protons in between).  
H2‘ protons exhibit a splitting of ~50Hz, while H1‘ and H3‘ protons are split by 15 
Hz and 27 Hz, respectively.  Except for U14, all pyrimidine H1‘ and H2‘ resonances 
were located.  All 13 fluorine resonances were observed in the spectrum.  
Additionally, all but five of the 13 pyrimidine H3‘ resonances were observed.   It is  
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Figure 3.2 
19
F-
1
H HMQC collected on the Macugen-HBD complex.   The
19
F-
1
H 
HMQC was collected in 100% D2O on a 500 MHz instrument at 25ºC.  The spectrum 
is expanded in three regions and peaks are labeled with final assignments.  Additional 
details are given in Figure 3.3. 
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Figure 3.3 Features of the 2D 
19
F, 
1
H HMQC spectra collected on the Macugen-HBD 
complex.  The above figure shows the 
19
F, 
1
H HMQC focused on three individual 
fluorine resonances.  Pyrimidine protons that exhibit scalar coupling to the 2‘-F group 
will appear as cross-peaks correlated to the 
19
F resonance.  Because the experiment 
was performed with no 
19
F decoupling during acquisition (t2), protons will show 
coupling in this dimension.  Coupled peaks are designated ‗a‘ and ‗b‘ to denote the 
upfield/downfield components.  H2‘ protons will display a coupling to fluorine of 
~50 Hz to the fluorine.  The coupling of fluorine to H2‘ and H3‘ protons is smaller; 
the former displays a coupling of ~15 Hz , while the H3‘ protons exhibit a coupling 
of ~27 Hz.  The H1‘ is usually located farthest upfield, followed by the H2‘ and H3‘.           
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possible that some H3‘ resonances were not observed due to overlap with water.  
Though the sample was in D2O, the presence of water is unavoidable.  Because water 
has a chemical shift of 4.77 ppm, it is possible its signal overlaps with some H3‘ 
resonances (3.9-5.0 ppm).  Notably, only one resonance is seen for U14 (assigned 
through process of elimination), and this was later found to correspond to its H2‘ 
proton.  The extreme downfield shift of the H2‘ of U14 is discussed later in the text.  
The signal-to-noise was not adequate to assign the coupled components of the H3‘ of 
C22 in the 
19
F, 
1
H HMQC, although the coupled pair was clearly defined in the 
19
F, 
1
H HOESY spectrum.   The information obtained from this experiment was extremely 
valuable.  Although resonances were not able to be assigned to their sequence-
specific nucleotides from this experiment alone, the H1‘, H2‘, and H3‘ resonances 
were identified with little ambiguity.  Furthermore, identification of pyrimidine sugar 
proton resonances from the 
19
F, 
1
H HMQC was critical for correct analysis of 
subsequent spectra.   
 
3.4 Validation of pyrimidine H1’, H2’, and H3’ resonances and analysis of 
sequential information from the 2D 
19
F, 
1
H HOESY  
 2D 
19
F, 
1
H heteronuclear Overhauser effect spectroscopy (HOESY) was used 
to confirm the pyrimidine H1‘, H2‘, and H3‘ sugar resonances obtained from the  
19
F, 
1
H HMQC, and was also used to identify the chemical shift of the H6 or H8 of 
residues directly following pyrimidines in the 5‘ to 3‘ direction.  This experiment 
identifies protons that are <5Å from the 2‘-F group of pyrimidines.  Figure 3.4 shows 
the 2D 
19
F, 
1
H HOESY with final assignments.  Importantly, 
19
F-
1
H NOE cross-peaks  
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Figure 3.4 
19
F-
1
H HOESY collected on the Macugen-HBD complex.  The
19
F-
1
H 
HOESY was collected in 100% D2O on a 500 MHz instrument at 25ºC with a mixing 
time of 300 ms.   
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can be observed between
 
intra-residue pyrimidine H1‘, H2‘, and H3‘ sugar protons 
and the 2‘-F.  Accordingly, this experiment can be used to validate the pyrimidine 
sugar resonances that were identified through the 
19
F, 
1
H HMQC experiment.  All 
pyrimidine sugar resonances identified in the 
19
F, 
1
H HMQC were also observed in 
this experiment, making these assignments robust.  Additionally, the signal-to-noise 
of this spectrum is better than that of the 
19
F, 
1
H HMQC, so several additional sugar 
assignments were made.  U14 shows weak peaks for the H1‘ and H3‘ protons, and 
they exhibit the expected splitting (15 Hz and 27 Hz, respectively) for these 
resonances.  Because these peaks lie at distinct chemical shifts, they cannot be 
attributed to other pyrimidine sugar resonances.  The better signal-to-noise of this 
spectrum compared to the 
19
F, 
1
H HMQC also provided for the assignment of the 
coupled components of the H3‘ of C22.   
 The 
19
F, 
1
H HOESY is a powerful tool because it can provide information 
about the position of pyrimidines in the sequence.  Like unmodified nucleotides,  2‘-F 
pyrimidines exhibit C3‘-endo sugar puckers, and RNA containing this group will tend 
to adopt A-form geometry (especially in helical regions) [56].  In this conformation, 
the 2‘-F group will lie within 5 Å of the H6 or H8 of the following residue in the 5‘ to 
3‘ direction, and an inter-residue 19F-1H NOE should be observed in the 19F, 1H 
HOESY.  Figure 3.5 shows the observable intra- and inter-residue NOEs in the 
19
F, 
1
H HOESY. Eleven such NOEs were observed in the spectrum.  Figure 3.6 shows 
how the 
19
F, 
1
H HOESY can be used to both validate the sugar assignments made 
from the 
19
F, 
1
H HMQC and to obtain sequential information.  In Macugen, it is 
possible that some pyrimidines in the internal bulge and hairpin do not adopt A-form  
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Figure 3.5 Observable Macugen NOEs in the 
19
F, 
1
H HOESY spectrum.  Blue lines 
indicate heteronuclear NOEs between the 2‘-F of pyrimidines and intra-residue ribose 
protons (H1‘, H2‘, and H3‘). The 2‘-F group lies too far away from the intra-residue 
H6 to exhibit an NOE to this proton, but it can show an NOE to the H6/H8 of the 
following residue in the 5‘ to 3‘ direction (red line).  The NOEs were predicted with 
the assumption that the RNA adopts A-form geometry.   
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Figure 3.6 Comparison of the 2D 
19
F, 
1
H HMQC (blue) and 
19
F, 
1
H HOESY (yellow) 
spectra of the Macugen-HBD complex.   Panels A) and B) show the 
19
F, 
1
H HOESY 
and 
19
F, 
1
H HMQC spectra (respectively) focused on the 2‘-F resonance of U6.  As 
with the 
19
F, 
1
H HMQC, intra-residue NOEs between the fluorine and H1‘/ H2‘/ H3‘ 
nuclei appear in the 
19
F, 
1
H HOESY spectrum due to their proximity to the fluorine.   
The HOESY experiment also reveals an additional NOE between the fluorine and the 
H6/H8 of the residue immediately following the pyrimidine in the 5‘ to 3‘ direction.  
In this case, the 2‘-F of U6 shows an NOE to the H6 of C7.  Panels C) and D) show 
an additional example using U20. Because it gives both intra- and inter-residue 
information, the 
19
F, 
1
H HOESY is valuable during the assignment process.    
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geometry, and these nucleotides may not show such inter-residue NOEs.  Both 
residues that did not exhibit these NOEs lie in these regions; U14 is located in the 
hairpin loop while C22 is positioned in the internal bulge.  Overall, this information 
was extremely valuable because it helped to simplify base-to-sugar walks; there was 
little ambiguity with regards to the base protons of residues following most 
pyrimidines in the sequence.  Table 3.2 provides the chemical shifts of the 
resonances assigned in the 
19
F, 
1
H HOESY experiment.  
 
3.5 Analysis of the 2D 
1
H, 
1
H NOESY in D2O on the Macugen-HBD complex to 
make sequential assignments 
 Though previous experiments were useful for identifying types of resonances, 
until this point in the assignment process, not enough information existed to assign 
resonances to specific residues of Macugen.  A 2D 
1
H, 
1
H NOESY, in conjunction 
with the previous experiments, was used to complete the assignment process.  A 
series of sugar-to-base walks were conducted in the 
1
H, 
1
H NOESY spectrum.  
Pyrimidine sugar resonances were first correlated to their intra-residue base 
resonances.  Base-to-sugar walks were then used to piece together consecutive 
pyrimidines and the spectrum was also used to identify H8 resonances of purines 
following pyrimidines in the sequence.  Also, by taking advantage of the unique 2‘-
OMe purine modifications in Macugen, residues following purines in the sequence 
were readily identified.   Additionally, T28, the sole 2‘-deoxy residue (found at the 
terminus of the nucleic acid), provides additional unique features that were utilized to 
obtain sequence-specific information from the 
1
H, 
1
H NOESY. 
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 Figure 3.7 shows the observable 
1
H-
1
H NOEs between atoms involved in 
sugar-to-base walks in the 
1
H, 
1
H NOESY spectrum.  Protons that lie within 5Å of 
each other will show NOEs in this experiment, and the figure assumes that the RNA 
adopts A-form geometry. As mentioned previously, nucleotides containing 2‘-F 
groups are found in C3‘-endo conformations, and will therefore tend to adopt A-form 
geometry (especially in helical regions) [56].  Likewise, nucleic acids containing 2‘-
OMe moieties also exhibit this geometry [57].  Therefore, Macugen is similar to 
unmodified RNA in that it likely adopts this conformation in helical regions.  It 
should be noted that there are a variety of inter-residue 
1
H-
1
H NOEs that can be 
observed when RNA is found in the A-form conformation.  The H3‘, H2‘, and 2‘-
OMe protons will show NOEs to the H6 or H8 of the following nucleotide in the 
sequence in the 5‘ to 3‘ direction.  This is important because it provides multiple 
means by which sequential information can be validated.  For example, if the H2‘ 
resonance of a purine is too overlapped to unambiguously identify, the walk can still 
be performed as long as either the H3‘ or 2‘-OMe resonances are not obscured.   
Because there are at least three protons that can exhibit inter-residue NOEs to the next 
residue in the sequence, the probability of a base-to-sugar walk being interrupted is 
significantly reduced.  Likewise, there are a variety of sugar protons that are within 5 
Å of their intra-residue base H6/H8 proton.  The H1‘, H2‘, and H3‘ are all close 
enough to the base proton to exhibit an NOE.  Hence, if one of the sugar resonances 
is overlapped, there are still two more protons that can be used to link sugar 
resonances to their intra-residue base.  Again, this reduces the probability of 
incomplete base-to-sugar walks. 
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Figure 3.7   Observable 
1
H-
1
H NOEs between atoms involved in sugar-to-base walk 
in the 
1
H, 
1
H NOESY spectrum (assumes A-form geometry).  Intra-residue NOEs are 
depicted with solid blue arrows connecting the atoms.   Solid red arrows depict inter-
residue (sequential) NOEs.  The dashed blue arrow between the 2‘-OMe of the 
adenosine and the intra-residue H8 indicates an NOE that likely results from spin 
diffusion (due to the nuclei being separated by more than 5 Ǻ.  Similarly, inter- 
residue NOEs between the H1‘ and the H6/H8 of the following (5‘ to 3‘) residue are 
also likely due to spin diffusion, and these NOEs are indicated with dashed red lines.   
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Figure 3.8 shows the distances between intra- and inter-residue base protons (H6 or 
H8) and H1‘/H2‘ sugar protons, while Figure 3.9 shows the distances between intra- 
and inter-residue base protons (H6 or H8) and H3‘/2‘-OMe sugar atoms. 
 NOEs can also be observed between protons if spin diffusion is occurring.  
Spin diffusion is a process that results in an apparent NOE between atoms that may 
be farther from each other than the 5Å limit for NOE formation [58].   For example, 
even though the 2‘-OMe is about 5.2 Å from its intra-residue H6 base proton, an 
NOE was observed between these nuclei in the spectra (Figure 3.9).  Additionally, 
spin diffusion NOEs may be seen between H1‘ protons and the H6/H8 of following 
residues.  Measurements indicate that this distance is ~5 Ǻ, and it is possible that 
some NOEs observed between these nuclei may be the result of spin diffusion if the 
distance is >5 Ǻ (Figure 3.8).  Spin diffusion can occur in NOESY experiments with 
long mixing times, and the 200 ms mixing time for the 
1
H, 
1
H NOESY experiment 
provided ample time for spin diffusion to occur.  Spin diffusion NOEs between the 
2‘-OMe and its intra-residue H8 were observed in the 1H, 1H NOESY spectrum.  
Though spin diffusion is sometimes unwanted, it is useful in the assignment of 
Macugen because it provides another means by which intra and inter-residue NOEs 
can be validated.  For example, if the H3‘ of a purine is severely overlapped, the 2‘-
OMe or H1‘ can still be used to link the sugar with the intra-residue base.  Likewise, 
if pyrimidine H2‘ and H3‘ resonances are severely overlapped, a spin diffusion NOE 
between its H1‘ and the H6/H8 of the following residue can avoid an interruption in 
the sugar-to-base walk. 
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Figure 3.8 Intra-/inter-residue distances between base protons (H6 or H8) and 
H1‘/H2‘ atoms in A-form RNA. Panel A) shows the distance (in Å) between several 
H1‘ atoms in an A-form RNA helix and their intra-residue H6/H8  [57].  Also shown 
are the distances between H1‘ atoms and the H6/H8 of adjacent residues in the 3‘ 
direction.  Intra-residue distances range from ~3.5-4.0 Å, whereas inter-residue 
measurements average ~5.0 Å.  In the Macugen-HBD complex, observed inter-
residue proton-proton NOEs between H1‘ atoms and the H6/H8 of following residues 
may arise from spin diffusion.  Panel B) shows distances between H2‘ atoms and 
their own intra-residue H6/H8, as well as distances between H2‘ groups and the 
H6/H8 of adjacent residues in the 3‘ direction.  The A-form RNA model used for 
these measurements is the same as that used for H1‘ distances.  These intra-residue 
distances average ~2.1-2.5 Å, and inter-residue distances range from 3.5 to 3.8 Å.  
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Figure 3.9  Intra-/inter-residue distances between base protons (H6 or H8) and 
H3‘/2‘-OMe groups in A-form RNA   Panel  A) shows the distances (in Å) between 
several H3‘ atoms in an A-form helix and their intra-residue H6/H8.  The RNA used 
for these measurements is the same one used in Figure 3.8 [59]  .  Also shown are the 
distances between H3‘atoms and the H6/H8 of adjacent residues in the 3‘ direction.  
Intra-residue distances range from ~2.3-2.8 Å, whereas inter-residue measurements 
range from ~3.3-3.5 Å.  Macugen residues adopting an A-form (C3‘ endo) geometry 
should produce observable intra- and inter-residue NOEs between H3‘ atoms and 
base protons.  Panel B) shows distances between 2-OMe protons in A-form RNA and 
their own intra-residue H6, as well as distances between the 2‘-OMe atoms and the 
H6 of the following residue in the 3‘ direction.  These intra-residue distances average 
~5.35 Å, and inter-residue measurements average about 3.4Å.  Observed intra-residue 
proton-proton NOEs between the H8 and 2‘-OMe protons result from spin diffusion.   
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Pyrimidine intra-residue H5/H6 NOE cross-peaks were first located in the 
spectrum by overlaying the 2D 
1
H, 
1
H TOCSY onto the 2D 
1
H, 
1
H NOESY.  H5/H6 
NOE cross-peaks will directly overlap with the H5/H6 TOCSY peaks.  Figure 3.10 
shows the overlaid spectra.  This established pyrimidine H6 chemical shifts, which 
are used extensively during the sugar-to-base walk.  The next step was to correlate 
pyrimidine sugar H1‘, H2‘, and H3‘ resonances with their intra-residue base protons 
to form complete sets of pyrimidine resonances.  This was done by searching for H1‘, 
H2‘, and H3‘ resonances (identified from the HMQC and HOESY) along each 
pyrimidine H6 chemical shift since all three sugar resonances can exhibit NOEs to the 
base H6 proton.  H1‘,  H2‘,  and H3‘ protons may also have an NOE cross-peak with 
the H6 proton of the following residue if it happens to be a pyrimidine, so caution 
must be used to ensure that sugar  resonances are not correlated to the wrong H6.  Use 
of the 
19
F, 
1
H HOESY is invaluable for this procedure since it gives information 
about the chemical shift of the H6/H8 of the following residue.  The ribose protons of 
U14 and C22 did not show NOEs to a following residue, so correlation of their sugar 
resonances with the intra-residue base H6 was simplified.  All sugar resonances were 
able to be correlated to their intra-residue base protons by this method.  Figure 3.11  
and Figure 3.12 provide two examples of how combined use of the 
1
H, 
1
H TOCSY, 
19
F, 
1
H HMQC, 
19
F, 
1
H HOESY, and 
1
H, 
1
H NOESY allowed for intra-residue 
correlation of pyrimidine sugar resonances with base H6/H5 protons.   
 To create robust footholds for extensive sugar-to-base walks, inter-residue 
NOEs were established for consecutive pyrimidines.  Additionally, a valuable  
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with H6-H5 TOCSY cross-peaks. 
   
 
Figure 3.10 Spectral overlay of the 2D 
1
H, 
1
H TOCSY (red) onto 
1
H, 
1
H NOESY 
(green) in the sugar-to-base region of the Macugen-HBD complex.  Both spectra of 
the Macugen-HBD complex were collected at 25ºC in 100% D2O.  The NOESY was 
acquired on an 800 MHz instrument using a 200 ms mixing time and presaturation 
water suppression.  Pyrimidine H6-H5 NOEs are identified by their direct overlap 
with H6-H5 TOCSY cross-peaks.   
 
 
 
U6H6-H5 
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Figure 3.11   Combined use of 2D 
19
F, 
1
H HMQC, 
19
F, 
1
H, 
1
HOESY , 
1
H, 
1
H 
NOESY, and 
1
H, 
1
H TOCSY collected on the Macugen-HBD complex to correlate 
pyrimidine sugar resonances with intra-residue base protons A)  The region of the 
19
F, 
1
H HMQC spectrum of the Macugen-HBD complex displaying H1‘, H2‘, and H3‘ 
resonances of U6 correlated to the 2‘-F  B) Region of the 19F, 1H HOESY spectrum 
showing intra-residue NOEs between the 2‘-F and the H1‘, H2‘, and H3‘ of the 
pyrimidine.  The H6 chemical shift of the residue following U6 in the 5‘ to 3‘ 
direction (C7) is also observed in this spectrum.  C) The H6-H5 cross-peaks in the 
NOESY spectrum (green) were identified by overlaying the TOCSY (red).  The 
NOESY spectrum was then examined for NOEs between the H6 protons of U6 and its 
intra-residue H1‘, H2‘ and H3‘ sugar protons. 
 
1H, 1H NOESY 
19F, 1H HOESY 
19F, 1H HMQC 
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(Figure 3.12 continued) The H8 chemical shift of the residue following this 
pyrimidine in the 5‘ to 3‘direction (G11) is also observed. C) The 1H-1H NOESY 
spectrum (green) was examined for intra-residue NOEs between the H6 of U10 and 
its H1‘, H2‘, and H3‘ protons.   
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foothold was established by assigning the resonances of G27 and dT28.  Because 
dT28 contains a deoxy residue, it has unique methyl resonances from the H7, and its 
H2‘/H2‖ resonances can easily be found in the TOCSY and NOESY.  Figure 3.13 
shows the assignment of G27 and dT28.  Piecing together all consecutive pyrimidines 
was done with relative ease due to the fact that all sugar resonances had been defined 
through the HOESY/HMQC and because the HOESY reveals the chemical shift of 
the H6/H8 of the following residue.  Figure 3.14 provides an example of how 
pyrimidine-pyrimidine connectivities were established using the 
1
H, 
1
H NOESY.  
Finally, pyrimidines followed by purines were linked together using identified 
pyrimidine sugar resonances and information from the HOESY.  At this point, the 2‘-
OMe group was used to establish purine-pyrimidine links as well as purine-purine 
links. Figure 3.15 shows how the 2‘-OMe was used for sugar-to-base walks.  
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(Figure 3.13 continued) between these residues.  Finally, this panel also shows intra-
residue NOEs (as well as TOCSY peaks) between the H1‘ and H2‘/H3‘ of G27.   
Panel B)  shows intra-residue NOEs between the H6 of G27 and its own H1‘ and H2‘ 
protons.  Additionally, the H6 of dT28 exhibits intra-residue NOEs to its H1‘, H2‘, 
and H2‖ protons.  Inter-residue NOEs are seen between the H8 of G27 and the  H1‘ 
/H2‘/H2‖ of dT28.  Additional inter-residue NOEs are observed between the H6 of 
dT28 and the H1‘/H2‘/H3‘ of G27. 
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Figure 3.14 Use of inter-nucleotide 
1
H-
1
H NOEs to establish pyrimidine-pyrimidine 
connectivities.  Panel A)  shows the 
1
H, 
1
H TOCSY (red) overlaid onto the 
1
H, 
1
H 
NOESY (green) expanded on a single H6/H5 resonance belonging to U24.  H1‘/H2‘ 
protons show intra-residue NOEs to the H6 (solid line).  B) The chemical shift of the 
H6 was shown from the 
19
H, 
1
H HOESY to be 7.79 ppm, corresponding to the H6 of 
C25.  As expected, NOEs are seen between the H6 of C25 and the H1‘/H2‘ of U24 
(dotted lines).  Intra-residue NOEs are seen between the H6 of C25 and its H1‘/H2‘ 
protons (solid line)  C) The H6/H8 chemical shift of the residue following C25 in the 
sequence is t 7.55 ppm (from the HOESY), corresponding to the (CONTINUED) 
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(Figure 3.14 continued) H6 of C26.  D The H1‘/H2‘ of C25 show inter-residue 
NOEs to the H6 of C26 (dotted lines). Completing the walk, the H6 of C26 has NOE 
cross-peaks to its intra-residue H1‘/H2‘ atoms.   
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(Figure 3.15 continued) to G11.Continuing the walk, the H8 of G11 shows NOEs to 
its intra-residue H1‘, H2‘, and 2‘-OMe atoms, and the 2‘-OMe of G11 was located 
via its intra-residue NOEs to the H1‘ and H2‘ (not shown) as well as its spin diffusion 
NOE to the H8 (shown).  The spectrum was examined for inter-residue NOEs 
between the 2‘-OMe protons of G11 and the H6/H8 of the following (5‘ to 3‘) 
residue, and they were located at 8.4 ppm (shown with dotted lines within panel B).  
This corresponds to the H8 chemical shift of A12.  Completing this stretch of the 
base-to-sugar walk, the H8 of A12 exhibits intra-residue NOEs to its own H1‘ and 
H2‘ protons.  Thus, combined use of the intra- and inter-residue NOEs allowed for 
the establishment of pyrimidine-purine and purine-purine connectivities.  
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3.6 Conclusions 
 This work led to the assignment of all but four residues of Macugen.  These 
nucleotides lie in the internal bulge and the hairpin loop, and are probably in regions 
that do not exhibit A-form geometry.  Additionally, an interesting feature is seen in 
U14.  It‘s H2‘ resonances lie the farthest downfield—contrary to the usual pattern 
where H1‘ protons are found shifted the furthest downfield.  This could be due to a 
unique conformation of this residue since the H2‘ protons are likely experiencing the 
most electronegative environment. Figure 3.16 shows final NOE connectivities from 
sugar-to-base walks, and Table 3.3 gives the final assigned chemical shifts for all 
assigned residues.    
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Figure 3.16 Diagram of observed intra-molecular Macugen 
1
H-
1
H and 
1
H-
19
F NOEs 
in the Macugen-HBD complex.  Blue lines indicate intra-residue NOEs and red lines 
indicate inter-residue NOEs.  Dashed lines indicate NOEs likely from spin diffusion.
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APPENDIX 
List of Directories and Filenames 
 
A.1 Original 2D NMR data collected on the Macugen-HBD complex is in directory:  
     /libby/spectra/hbd-mac/092008/ 
hbdmac_tocsy_48ms_100408_ael 
hbdmac_19fhmqc_stoppedat214_72hrs_092208_ael 
hbdmac_hoesy_300ms_101008_ael 
hbdmac_noesy200ms_d2o_800_cold_100608v2_ael 
 
A.2 Original Sparky project used to assign Macugen in the complex is in directory: 
     /libby/sparky/projects/hbdmac/thesis/ 
libby_thesis_macugen_assignment_final_080210_ael 
